Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 16:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...
April 17, 2026 15:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of...
April 03, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response ...
April 02, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
April 01, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
March 31, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...
March 17, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...
March 10, 2026 05:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial...
February 04, 2026 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations...
February 03, 2026 21:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration...